A Randomized, Open Label, Single-center, Single-dose, Four-period Crossover Clinical Trial to Assess the PK Profile and Safety of Budesonide Inhalation Solution AQ001S Compared to Budesonide Inhalation Suspension in Healthy Volunteers

Aquilon Pharmaceuticals S.A.1 个研究点分布在 1 个国家目标入组 29 人开始时间: 2021年11月12日最近更新: 2022年11月3日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方
入组人数: 29
试验地点: 1
主要终点: Assessment of pharmacokinetics (Tmax) of budesonide through analysis of blood samples

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

详细描述

This is a randomized, open label, single-center, single-dose, four-period crossover clinical study to assess the pharmacokinetic profile and safety of a budesonide inhalation solution (AQ001S) compared to a budesonide inhalation suspension (comparator) in healthy volunteers. Three (3) different AQ001S concentrations (i.e. 0.125 mg/2 mL, 0.250 mg/2mL and 0.500 mg/2 mL) will be compared to budesonide inhalation suspension 1.0 mg/2 ml.

Twenty (20) male and female healthy volunteers, from 18 to 60 years old, must complete the study. The study drug will be administered by nebulization.

The primary PK objective is to characterize the pharmacokinetic (PK) profile of AQ001S inhalation solution.

The primary safety objective is to assess the safety of AQ001S inhalation solution.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 60 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•Subjects who have given written informed consent.
•Healthy volunteers of both genders, aged ≥ 18 and ≤ 60 years.
•Subjects with body weight > 45 kg and Body Mass Index ≥ 18.5 and ≤ 24.9kg/m
•Healthy volunteers are declared healthy based on medical history, physical examination, electrocardiogram, pulmonary function test (Forced Expiratory Volume in 1 second ≥ 80% of the predicted normal value and Forced Expiratory Volume in 1 second/ Forced Vital Capacity ≥ 70%).
•Clinical laboratory values within the laboratory stated normal range; if not within this range, they must be without any clinical significance according to the Investigator.
•Subjects who never smoked.
•Women of childbearing potential (WOCBP) may be enrolled if they practice a method of birth control with a reliability of at least 90% and agree to continue doing so throughout the treatment period (e.g. condom, intrauterine device or hormonal contraception).
•Any female subject with childbearing potential has a negative pregnancy test at Screening visit and prior to dosing at each treatment period.
•Reliable subjects who are willing to be available for the duration of the clinical study and willing to comply with clinical study procedures.
•Subjects who have the ability to understand the requirements of the clinical study.

排除标准

•Any clinically important abnormality identified at the screening medical assessment (physical examination/medical history) or clinically relevant laboratory abnormalities.
•Clinically significant history or presence of pulmonary malformations, chronic bronchitis, asthma, emphysema, cystic fibrosis or any other pulmonary disease
•History or presence of pulmonary tuberculosis.
•Viral or bacterial upper or lower respiratory tract infection, or sinus or middle ear infection, within 4 weeks prior to the screening visit.
•Untreated oral candidiasis.
•History or presence of prolonged QTc interval (> 450 ms), or any other clinically significant electrocardiogram abnormalities as judged by the Investigator based on 12-lead electrocardiogram recordings at Screening Visit.
•History or presence of malignancy of any system organ class (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years prior to Screening Visit, regardless of whether there is no evidence of local recurrence or metastases.
•Eye disorders, especially glaucoma, or a family history of glaucoma.
•History of alcohol or drug abuse.
•Inability to abstain from alcohol consumption for the duration of study period.
•Immunosuppressive treatment, including topical and systemic corticosteroids (e.g., oral, parenteral, ocular, nasal or inhaled), within 4 weeks before Screening Visit.
•Use of prescription or non-prescription drugs, except for simple analgesics (e.g. paracetamol) and hormonal contraception for women, including vitamins, herbal and dietary supplements (including St John's Wort [Hypericum]) within 7 days (or 2 weeks if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) before the Screening Visit.
•Pregnant or breastfeeding female subjects.
•History of hypersensitivity or existing contraindication to budesonide or any other study medication ingredients.
•Blood or plasma donation within 4 weeks prior to Screening Visit.
•Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the clinical study.
•History or presence of any other clinically relevant disease of any major system organ class (e.g. cardiovascular, pulmonary, renal, hepatic, gastrointestinal, reproductive, endocrinological including any type of Diabetes mellitus, neurological, psychiatric or orthopedic disease) as judged by the Investigator.
•COVID-19, Hepatitis B and C and HIV positive tests
•Any COVID-19 vaccine within 2 weeks prior to the first dose of study drugs, and during the entire study participation including 2 weeks after the last dose of study drug.
•Subjects who participated in an investigational study within the 12 weeks prior to the start of the study

研究组 & 干预措施

AQ001S 0.125 mg/2mL single-dose

Experimental

AQ001S 0.125 mg/2 ml (budesonide 0.125 mg/2 ml inhalation solution) single-dose administered by nebulization.

干预措施: Budesonide Inhalant Product (Drug)

AQ001S 0.250 mg/2mL single-dose

Experimental

AQ001S 0.250 mg/2 ml (budesonide 0.250 mg/2 ml inhalation solution) single-dose administered by nebulization.

干预措施: Budesonide Inhalant Product (Drug)

AQ001S 0.500 mg/2mL single-dose

Experimental

AQ001S 0.500 mg/2 ml (budesonide 0.500 mg/2 ml inhalation solution) single-dose administered by nebulization.

干预措施: Budesonide Inhalant Product (Drug)

Budesonide inhalation suspension 1.0 mg/2 ml single-dose

Active Comparator

Pulmicort Respules® 1.0 mg/2 ml is a budesonide inhalation suspension administered by nebulization.

干预措施: Budesonide Inhalant Product (Drug)

结局指标

主要结局

Assessment of pharmacokinetics (Tmax) of budesonide through analysis of blood samples

时间窗: Day 1 (predose) and at 2', 5', 10', 15', 20', 30', 45', 60', 90', 120', 180', 240', 360', 10h, 18h and 24h postdose

Blood samples will be collected from each subject using an indwelling intravenous catheter. In total 17 blood samples for PK assessments over 24 hours will be collected.

Assessment of pharmacokinetics (AUC) of budesonide through analysis of blood samples

时间窗: Day 1 (predose) and at 2', 5', 10', 15', 20', 30', 45', 60', 90', 120', 180', 240', 360', 10h, 18h and 24h postdose

Blood samples will be collected from each subject using an indwelling intravenous catheter. In total 17 blood samples for PK assessments over 24 hours will be collected.

Assessment of the safety through to incidence of Adverse Events of AQ001S inhalation solution